Jim Cramer Finds Pfizer (PFE)'s Stock Level "Unfathomable"

We recently published 12 Latest Stocks on Jim Cramer's Radar . Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed.

Jim Cramer has discussed pharma giant Pfizer Inc. (NYSE:PFE) several times recently. He has repeatedly commented on how the stock trades more like a bond rather than an equity due to its 7% dividend yield. In this appearance, he asked CEO Albert Bourla his opinion about the stale trading activity. In response, Bourla outlined that he agreed with Cramer that the stock was undervalued and his company had addressed concerns, including high tariffs, too much COVID revenue, and the firm’s strategy to address the weight loss drug market. Bourla added that the loss of exclusivity of Pfizer Inc. (NYSE:PFE)’s drugs was also a key concern, and his firm is working on it. As part of his question, Cramer also opined on Pfizer Inc. (NYSE:PFE)’s stock:

“Alright, so, Dr., I’m gonna ask a simple question, I know that you don’t control the stock market, [inaudible] but I thought the quarter was good that you just announced, and I thought for sure the stock would move up. What is it, do you think, that is keeping the stock at a 7% yield with a great balance sheet and a lot of stuff in the pipe? I find it unfathomable that your stock is still where it is.”

While we acknowledge the potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.